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Abnormalities in steroid hormones are responsible for the development and prevention of
endocrine diseases. Due to their biochemical roles in endocrine system, the quantitative
evaluation of steroid hormones is needed to elucidate altered expression of steroids. Gas
chromatographic-mass spectrometric (GC-MS) profiling of 70 urinary steroids, containing 22
androgens, 18 estrogens, 15 corticoids, 13 progestins, and 2 sterols, were validated and its
quantitative data were visualized using hierarchically clustered heat maps to allow “steroid
signatures”. The devised method provided a good linearity (r2  0.994) with the exception of
cholesterol (r2  0.983). Precisions (% CV) and accuracies (% bias) ranged from 0.9% to 11.2%
and from 92% to 119%, respectively, for most steroids tested. To evaluate metabolic changes,
this method was applied to urine samples obtained from 59 patients with benign prostatic
hyperplasia (BPH) versus 41 healthy male subjects. Altered concentrations of urinary steroids
found and heat maps produced during this 70-compound study showed also differences
between the ratios of steroid precursors and their metabolites (representing enzyme activity).
Heat maps showed that oxidoreductases clustered (5-reductase, 3-HSD, 3-HSD, and
17-HSD, except for 20-HSD). These results support that data transformation is valid, since
5-reductase is a marker of BPH and 17-HSD is positively expressed in prostate cells.
Multitargeted profiling analysis of steroids generated quantitative results that help to explain
correlations between enzyme activities. The data transformation and visualization described
may to be found in the integration with the mining biomarkers of hormone-dependent
diseases. (J Am Soc Mass Spectrom 2009, 20, 1626–1637) © 2009 American Society for Mass
SpectrometryMass spectrometry based metabolite profilingreveals the metabolic states of biological sys-tems and provides comprehensive insights by
allowing comparisons between many metabolites si-
multaneously present in cells, tissues, or organisms [1,
2]. This technique promotes the establishment of rela-
tionships between phenotypes and metabolisms by
providing descriptions of the distributions of metabo-
lites and their biological functions. In fact, quantitative
analyses of sets of metabolites in biochemical pathways
have been used for physiological monitoring, toxicolog-
ical evaluations, and clinical diagnosis [3–6].
Many naturally occurring steroids with similar
chemical structures could yield biological information
[7]. Endogenous steroids are divided into five groups,
namely, androgens, estrogens, corticoids, progestins,
and sterols, which are generally synthesized from cho-
lesterol in the adrenal cortex, ovaries, and testes
(Scheme 1). In biosynthetic pathways of steroid hor-
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doi:10.1016/j.jasms.2009.04.020mone, two major types of enzymes are involved, cyto-
chrome P450 and steroid oxidoreductase. Abnormalities of
these enzymes often lead to hormonal imbalances that
have serious consequences, and which are responsible
for the development of hormone-dependent diseases
(see Supplementary Table 1, which can be found in the
electronic version of this article). For example, concen-
trations of corticoids and their metabolic ratios provide
diagnostic evidence of apparent mineralocorticoid ex-
cesses caused by 11-HSD deficiency [8] and congenital
adrenal hyperplasia, which are caused by deficiencies
of enzymes like hydroxylase (at C-11, 17, and 21) or
3-HSD [9]. In addition, enhanced androgen activity
generated by the conversion of testosterone to dihy-
drotestosterone (DHT) by 5-reductase was utilized to
allow early therapeutic intervention in young men [10].
Enzyme activity profiles can be used to describe the
functional diversities of biological systems, which are
driven by genetic diversity. Although enzyme activities
have been monitored by following reactions between
targeted enzymes and substrate molecules, over-
estimations by radioimmunoassay (RIA) and enzyme
immunoassay (EIA), because of cross reacting antibod-
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more, only single enzymes can be estimated at a time
[11–14]. In contrast to conventional enzyme assays, gas
chromatography-mass spectrometry (GC-MS)-based
techniques have better quantitative reproducibility [15,
16]. For these reasons, GC-MS profiling has been widely
used for steroid analysis [17–20], and offers the basis for
techniques that can be applied to large-scale clinical
studies [21].
Clinical significances are generally expressed in ta-
bles or bar graphs that show changes in analytes across
groups of interest. For studies involving few com-
pounds, these visualizations are enough to differentiate
classes showing metabolic differences. However, quan-
titative datasets of multiple compounds are much more
difficult to represent visually. Statistical clustering of-
fers one such approach, and has been utilized to sup-
port genomic and proteomic studies [22–24]. In a simi-
lar fashion, quantitative results obtained by metabolite
profiling can be directly compared between samples
and utilized as metabolic biomarkers. In recent, MS-
based quantitative data generated by hierarchical clus-
tering analysis (HCA) has been subjected to pattern
analysis for metabolite profiling [2, 25]. The concept of
“metabolite signature” is a result of this process, and
such signatures are useful for measuring and visualiz-
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Scheme 1. General scheme for steroid metabo
names of steroid hormones.ing the relative analyte concentrations. Although manygroups have used GC-MS based steroid analysis for
mining biomarkers, technical improvements that more
effectively allow the visualization of steroid metabolites
are required [26]. However, no studies have reported
MS-based steroid signatures generated by HCA to date.
Here, we introduce the GC-MS quantitative profiling
of 70 urinary steroids, including 22 androgens, 18
estrogens, 15 corticoids, 13 progestins, and 2 sterols,
generated by HCA to evaluate metabolic changes and
enzyme reactions in steroid analysis. The aim of this
study was to validate a GC-MS profiling method and a
method that allows the quantitative visualization of
multiple urinary steroids. To visualize quantitative re-
sults, a microarray map (a type of heat map) was
designed to present the urine sample results of 59
patients with benign prostatic hyperplasia (BPH) and 41
healthy male subjects; BPH was chosen because steroid
metabolism is known to play a role in the progress of
prostate diseases [27–29]. This study focused on illus-
trating the usefulness of steroid signatures for explain-
ing both the concentrations of individual steroids and
the activities of enzymes correlated global steroidogen-
esis in BPH, and suggest that enzyme activity profiling
may be a useful diagnostic tool and provide a means of
identifying mining biomarkers in hormone-dependent
drogens
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Chemicals and Materials
Reference standards of the 70 steroids examined in this
study (Table 1) were obtained from Sigma (St. Louis, MO,
USA), Steraloids (Newport, RI, USA), or NARL (Pumble,
Australia). The internal standards used were, 16,16,17-d3-
testosterone and methyltestosterone for 22 androgens,
2,4,16,16-d4-estradiol for 18 estrogens, 9,11,12,12-d4-cortisol
for 15 corticoids, 2,2,4,6,6,17,21,21,21-d9-progesterone
and 2,2,4,6,6,21,21,21-d8-17-hydroxyprogesterone for 13
progestins, and 2,2,3,4,4,6-d6-cholesterol for 2 sterols were
purchased from NARL and C/D/N isotopes (Pointe-
Claire, Quebec, Canada). For solid-phase extraction (SPE),
Oasis HLB cartridge (3 mL, 60 mg; Waters, Milford, MA,
USA) was preconditioned with 3 mL of methanol fol-
lowed by 3 mL of deionized water. Sodium acetate (re-
agent grade), acetic acid (glacial, 99.99%) and L-ascorbic
acid (reagent grade) were obtained from Sigma (St. Louis,
MO, USA). A solution of -glucuronidase/arylsulfatase
fromHelix pomatiawas purchased fromRoche Diagnostics
GmbH (Mannheim, Germany). The trimethylsilylating
(TMS) agents, N-methyl-N-trifluorotrimethylsilyl acet-
amide (MSTFA), ammonium iodide (NH4I), and dithio-
erythritol (DTE) were purchased from Sigma. All organic
solvents used were of analytical or HPLC grade and were
purchased from Burdick and Jackson (Muskegan, MI,
USA). Deionized water was prepared using the Milli-Q
purification system (Millipore, Billerica, MA, USA).
Standard Solutions and Quality-Control Samples
Stock solutions of all reference standards were prepared
at a concentration of 1000 g/mL in methanol and
working solutions were made up with methanol at
concentrations in the range 0.1 to 10 g/mL. L-Ascorbic
acid (1 mg/mL) was added to prevent the oxidations of
labile steroid metabolites. All standard solutions were
stored at 20 °C until required and all were stable for a
minimum of 3 mo. The urine samples used for calibra-
tion and quality-control (QC) purposes were prepared
in house from steroid-free urine [30]. Steroids-free urine
samples were prepared by percolating urine samples
through Serdolit PAD-1 (0.1–0.2 mm analytical grade;
Serva, Heidelberg, Germany). In this way, urinary ste-
roids and other potential interfering compounds are
retained in the cartridges and the eluates were collected.
After checking for endogenous steroids with negative
result following the solvent extraction procedure, they
were used as matrix for steroid profiling.
Subjects and Sample Collection
First-morning urine samples were collected from 59
BPH patients (age: 65.3  8.2 y male) and 41 healthy
male subjects (age: 56.7  7.1 y) in the Department of
Urology at Severance Hospital (Seoul, Korea). All pa-
tients underwent a transrectal ultrasound-guided oc-tant biopsy and had either a suspicious finding by
digitorectal examination or an elevated level of serum
prostate-specific antigen (PSA). The age-matched nor-
mal controls showed no evidence of serum PSA level
elevation or of BPH. Steroid levels in urine were nor-
malized versus urinary creatinine values using Jaffe
method [31].
Sample Preparation
Quantitative metabolite profiling of urinary steroids
was based on previous reports [4, 8, 32]. Briefly, urine
samples (2 mL) spiked with 20 L of the 7 internal
standards (d3-testosterone and d4-estradiol; 1 g/mL,
d4-cortisol and d8-17-hydroxyprogesterone; 5 g/mL,
methyltestosterone, d9-progesterone, and d6-cholesterol
to 10 g/mL) were extracted with Oasis HLB SPE
cartridges coupled to a peristaltic pump. After loading
a sample onto a cartridge, the cartridge was washed
with 2 mL water and eluted twice with 2 mL of
methanol. Combined methanol eluates were evapo-
rated under a stream of nitrogen and then 1 mL of 0.2 M
acetate buffer (pH 5.2), 100 L of aqueous 0.2% ascorbic
acid, and 50 L of -glucuronidase/arylsulfatase were
was added. After incubation at 55 °C for 3 h, the
solution was extracted twice with 2.5 mL of ethyl
acetate: n-hexane (2:3, vol/vol). Combined organic sol-
vents were evaporated using a N2 evaporator at 40 °C
and further dried in a vacuum desiccator over P2O5-
KOH for at least 30 min. Finally, the dried residue was
derivatized with MSTFA/NH4I/DTE (40 L; 500:4:2,
vol/wt/wt) at 60 °C for 20 min, and 2 L of the
resulting mixture was subjected to GC-MS in selected-
ion monitoring (SIM) mode. To maximize extraction
efficiencies, two organic solvents, tetrahydrofuran
(THF) and ethyl acetate, were evaluated in the pH range
5 to 9. In addition, the potential uses of diethyl ether,
methyl tert-butyl ether, and n-hexane were investigated
for promoting the partition of water-miscible THF and
ethyl acetate.
Instrumental Conditions
GC-MS was performed with an Agilent 6890 Plus gas
chromatograph interfaced with a single-quadrupole
Agilent 5975 MSD at an electron energy of 70 eV and an
ion source temperature of 230 °C. Each sample (2 L)
was injected in split mode (10:1) at 280 °C and separated
through an Ultra-1 capillary column (25 m  0.2 mm
i.d., 0.33 m film thickness; Agilent Technologies; Palo
Alto, CA, USA). The GC oven temperature was initially
set at 215 °C, then ramped to 260 °C at 1 °C/min, and
finally increased to 320 °C at 15 °C/min and held for 1
min. The carrier gas was helium at a column head
pressure of 210.3 kPa (column flow: 1.0 mL/min at oven
temperature of 215 °C). For quantitative analysis, char-
acteristic ions of each steroid were determined as their
TMS derivatives. Peak identifications were achieved by
Table 1. The GC-MS information for quantitative analysis of steroids studied
Compounds (trivial name) Abbreviation
Ion
selecteda
Retention
time
(min) Compounds (trivial name) Abbreviation
Ion
selected
Retention
time
(min)
Androgens Estrogens
5-androstan-3,17-diol -diol 256 12.12 17-estradiol 17-E2 416 18.60
5-androstan-3,17-diol -diol 256 12.87 Estrone E1 414 19.12
Androsterone An 434 15.27 17-estradiol 17-E2 416 19.98
Etiocholanolone Etio 434 15.44 2-methoxy-17-estradiol-3-
methylether
2-MeO-E2-3-methylether 388 23.40
5-androstan-3,17-diol -diol 241 16.00
5-androstan-3,17-diol -diol 256 16.07 4-methoxy-17-estradiol 4-MeO-E2 446 23.73
5-androstan-3,17-diol -diol 241 17.04 2-methoxyestrone 2-MeO-E1 444 24.57
Epidihydrotestosterone Epi-DHT 434 17.46 2-hydroxy-17-estradiol-3-methylether 2-OH-E2-3-methylether 446 25.06
11-keto-androsterone 11-keto-An 520 17.55
11-keto-etiocholanolone 11-keto-Etio 520 17.60 2-methoxy-17-estradiol 2-MeO-E2 446 25.53
Dehydroepiandrosterone DHEA 432 17.85 2-hydroxyestrone 2-OH-E1 502 25.92
Epiandrosterone Epi-An 419 18.10 2-hydroxy-17-estradiol 2-OH-E2 504 26.75
Androstenediol A-diol 434 18.58 4-hydroxyestrone 4-OH-E1 502 27.34
5-Androstanedione 5-dione 432 18.60 4-hydroxy-17-estradiol 4-OH-E2 504 28.42
Epitestosterone Epi-T 432 18.77 17-epiestriol 17-epi-E3 504 29.19
5-androstan-3,17-diol -diol 241 18.83 Estriol E3 504 29.82
Dihydrotestosterone DHT 434 19.34 16-keto-17-estradiol 16-keto-E2 487 30.06
Androstenedione A-dione 430 19.80 16a-hydroxyestrone 16-OH-E1 487 30.06
Testosterone T 432 20.52 16-epiestriol 16-epi-E3 504 31.16
11-hydroxyandrosterone 11-OH-An 522 20.73 2-hydroxyestriol 2-OH-E3 592 37.30
11-
hydroxyetiocholanolone
11-OH-Etio 522 21.05 d4-17 -estradiolb d4-E2 420 19.88
16-hydroxy-DHEA 16-OH-DHEA 505 28.49
d3-testosteroneb d3-T 435 20.44
Methyltestosteroneb Methyl-T 446 24.21
Corticoids Progestins
Tetrahydrodeoxycortisol THS 548 34.98 5-dihydroprogesterone 5-DHP 445 20.01
TetrahydrodeoxycorticosteroneTHDOC 550 36.26 Epipregnanolone Epi-P-one 447 23.33
Tetrahydrocortisone THE 634 38.66 Pregnanolone P-one 447 23.62
Tetrahydrocortisol THF 636 41.30 Allopregnanolone Allo-P-one 447 23.97
Dihydrodeoxycorticosterone DHDOC 548 42.03 Pregnanediol P-diol 269 25.03
Allotetrahydrocortisol Allo-THF 636 42.39 Pregnanetriol P-triol 435 26.34
21-deoxycortisol 21-deoxyF 634 42.55 Pregnenolone Preg 445 27.36
11-deoxycortisol 11-deoxyF 544 42.76 5-dihydroprogesterone 5-DHP 445 28.57
11-deoxycorticosterone 11-deoxyB 546 43.51 Progesterone Prog 458 29.90
Cortisone E 615 46.03 20-hydroprogesterone 20-DHP 445 30.20
11-dehydrocorticosterone 11-dehydroB 617 46.80 17-hydroxypregnenolone 17-OH-Preg 548 32.68
Allodihydrocorticosterone Allo-DHB 636 46.87 17-hydroxyprogesterone 17-OH-Prog 546 35.70
Allodihydrocortisol Allo-DHF 634 47.01 11-hydroxyprogesterone 11-OH-Prog 531 41.32 1629
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1630 MOON ET AL. J Am Soc Mass Spectrom 2009, 20, 1626–1637comparing retention times and matching the height
ratios of characteristic ions (Table 1).
Method Validation
QC samples containing all 70 analytes were quantified
using MS peak height ratios versus the IS. Calibration
samples were made up at 15 different concentrations,
which depended on the sensitivity and reference values
of the urinary steroids. Least-squares regression analy-
sis was performed on peak height ratios at increasing
analyte levels to obtain calibration linearity. Limits of
detection (LOD) and quantification (LOQ) were defined
as the lowest concentration with a signal-to-noise (S/N)
ratio  3 for LOD and of S/N ratio  10 for LOQ.
Precisions are expressed as coefficients of variation (%
CV) and accuracies as percent relative errors (% bias),
and were determined using QC samples at three differ-
ent concentrations (low; 2  50 ng/mL, medium; 20 
200 ng/mL, and high; 100  2000 ng/mL) depending
on the sensitivity and reference values of the urinary
steroids. To determine within-day repeatabilities, four
replicates were analyzed, whereas day-to-day repro-
ducibility was measured by running samples on 5
different days.
Extraction recoveries were determined using QC
samples at three concentration levels in triplicate for
each steroid by adding known amounts of mixed work-
ing solutions to steroid-free urine samples. Absolute
recoveries were calculated by comparing peak height
ratios of extracted samples versus those of their nonex-
tracted counterparts, using the IS added just before the
derivatization step.
Statistical Analysis and Steroid Signatures
Data manipulation was performed using Excel 2007
spreadsheets (Microsoft Corp., Seattle, WA, USA), Sig-
maplot (SYSTAT Software Inc., San Jose, CA, USA), and
SIMCA software (Umetrics Inc., Umeå, Sweden). Quan-
titative results are expressed as means  SD, and group
comparisons are made using the unpaired two-tailed
Student’s t-test. Statistical significance was considered
at P  0.01.
To visualize differences between the steroid signa-
tures of BPH patients and healthy subjects, a supervised
hierarchical clustering algorithm based on Pearson’s
correlation coefficient was used with a TIBCO Spotfire
DecisionSite Browser (TIBCO Spotfire, Inc., Somerville,
MA, USA). Concentrations of steroids and ratios of
metabolites to precursors (an indicator of enzyme ac-
tivity) in BPH patients and healthy subjects were com-
pared using the Student’s t-test, and statistically sig-
nificant variables were selected and processed. For
clustering analysis, all prefiltered quantitative results of
steroids measured and their ratios were log trans-
formed and normalized using z-scores by subtracting
population means from individual raw scores and di-
viding the result by the population standard deviation.Ta C
C C d
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u
b
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median)/baseline standard variation] ensures that each
analyte in the subject population has a median value of
0 and a standard deviation of 1. In the heat map
generated using HCA, color coding in maps indicating
auto range by difference of concentration in each com-
pound was gradated at three point; red indicates z-
scores  0, blue z-scores  0, and white z-scores 	 0 of
a row (subjects) across all columns (urinary steroids).
Results and Discussion
Urinary Steroid Profiling
Steroid hormones of significance under different biolog-
ical conditions fall into several distinct groups, and are
frequently used to evaluate endocrine functions. Com-
prehensive extraction methods for GC-MS based ste-
roid analysis mainly focus on specific steroid metabo-
lites which have the same biological function and
chemical structures [15–17, 19]. Due to the chemical and
physical diversities within androgens, estrogens, corti-
coids, progestins, and sterols, the described profiling
technique was devised to simultaneously quantify ste-
roid analytes as diverse as lipophilic cholesterol and
hydrophilic corticoids in a single extract.
In SPE experiment, urinary steroids are purified
using a unique copolymer sorbent, Oasis HLB, which
allows high and reproducible results to be obtained [8,
30, 32, 33]. In general, SPE absorbent retains steroids
based on hydrophobic interactions with free and con-
jugated steroids. The following two extractions meth-
ods were therefore investigated: (1) 2 mL of urine was
processed with a SPE cartridge and the sample obtained
was hydrolyzed, and (2) urine was first hydrolyzed and
then processed in SPE. However, difficulties in loading
samples into SPE cartridges after hydrolyzing them
with -glucuronidase/arylsulfatases, due to an increase
in the viscosity of urinary solution hydrolyzed, were
observed. This result was not observed if -glucuronidase
only was present in the enzyme solution [6]. Therefore,
SPE procedure was processed first in sample prepara-
tion steps.
Although catechol estrogens, such as 2-OH-E1, 2-OH-
E2, 4-OH-E1, 4-OH-E2, and 2-OH-E3, are degraded when
exposed to light or to a pH higher than 9.5 [34], 0.2%
aqueous L-ascorbic acid was added to prevent oxidative
decomposition before enzymatic hydrolysis. After enzy-
matic hydrolysis, deconjugated steroids were extracted
with an ethyl acetate: n-hexane (2:3, vol/vol) mix. In
extraction, THF and ethyl acetate were primarily investi-
gated, and diethyl ether, t-butyl methyl ether, and n-
hexane were added to expedite THF and ethyl acetate
partitioning. When relatively polar organic solvents, such
as diethyl ether and t-butyl methyl ether, were used,
chromatographic interference was encountered. Although
both THF and ethyl acetate had high extraction efficien-
cies, ethyl acetate was finally selected because of the
objectionable smell and high polarity of THF.Overall extraction efficiencies were not signifi-
cantly different for all steroids studied at pH values
of 5 to 7. The recoveries of catechol estrogens (10.4%
 48.9%) were poor at pH 9 because they are oxidized
to quinones at this pH [35]. In addition, different
ratios of ethyl acetate to n-hexane were examined and
a 2:3 (vol/vol) mix was chosen having considered
extraction yield and chromatographic properties. Us-
ing optimized conditions, all urinary steroids studied
were extracted in good yields, except 2-OH-E3 and
24S-OH-Chol, which are still detectable in urine after
extraction (Figure 1).
Gas Chromatography-Mass Spectrometry
Using the described GC-SIM/MS conditions, 70 steroid
hormones were analyzed as their TMS derivatives and
peak identification was straightforward using retention
times, characteristic ions, chromatograms, and mass
spectra, the latter were compared with those of refer-
ence standards. The GC oven program used resulted in
well separated, good peak shapes for most steroids with
retention times from 12.12 min for -diol to 48.99 min
for 24S-OH-Chol. On the other hand, 11-keto-An and
11-keto-Etio, and 16-keto-E2 and 16-OH-E1 were co-
eluted and estimated totally in quantification (Figure 2).
However, some partial-overlapped compounds (e.g.,
5-dione and 17-E2, 2-OH-E2-3-methylether and P-
diol, 4-OH-E1 and Preg) were differentiated by SIM
using their different characteristic ions (Table 1).
Most steroids were monitored using their molecular
ions as base peaks, except: -diol, -diol, -diol,
which had an abundant [M-180; M-2OTMS] ion at m/z
256; -diol, -diol, -diol with an [M-195;
M-2OTMS-CH3]
 ion at m/z 241; 5-DHP, 5-DHP,
Preg with an [M-15; M-CH3]
 ion at m/z 445; Epi-P-one,
P-one, and Allo-P-one with an [M-15] at m/z 447;
16-keto-E2, 16-OH-E1 with an [M-15] ion at m/z 487;
THS with an [M-90; M-OTMS] ion atm/z 548; THE and
Allo-DHF with an [M-90] ion at m/z 634; THF and
Allo-THF with an [M-90] ion at m/z 636; 11-deoxyF
with an [M-90] ion at m/z 544; cortisone (E) with an
[M-90-15; M-OTMS-CH3]
 ion at m/z 615; and 11-
dehydroB with an [M-15] at m/z 617. In the cases of
P-diol, P-triol, and 11-OH-Prog, less intense fragments
at m/z 269, 435 and 531, respectively, were chosen to
improve selectivity rather than most intense peaks (m/z
117, 255, and 546); this was attributed to urinary inter-
ference. Regarding the TMS ethers of P-diol and P-triol,
the characteristic ions at m/z 269 and 435 were moni-
tored, which are attributed to [M-195; M-2OTMS-CH3]

and [M-117; M-CH[OSi(CH3)3]CH3 side-chain]
 ions.
The base peak of P-diol is m/z 117 and other important
fragments are m/z 269 [M-90-90-15], m/z 284 [M-90-
90], m/z 347 [M-117], and m/z 449 [M-15]. Among
these fragments, m/z 269 instead of m/z 117 was chosen
to improve selectivity from urinary backgrounds. Also
the P-triol has m/z 255 [M-117-90-90], m/z 345 [M-117-
90], and m/z 435 [M-117] as major fragments formed
1632 MOON ET AL. J Am Soc Mass Spectrom 2009, 20, 1626–1637by the loss of 117 mass units, butm/z 435 was monitored
to improve selectivity. In addition, 11-OH-Prog elutes
THF at the similar retention time (41.30 min), but a
typical loss of 90 Da (-OTMS) from the THF (m/z 636)
would interfere the detection of 11-OH-Prog in case of
using m/z 546, the molecular ion. Therefore, m/z 531
[M-90-15], which rarely did not exist in THF, was
chosen instead of m/z 546 (see Supplementary Figure 1).
Method Validation
Method validation requires the evaluations of linearity,
LOD, LOQ, precision, and accuracy using calibration
samples prepared from in-house steroid-free urine [30].
Calibration curves were generated for all analytes using
QC samples fortified with all reference standards at
Figure 1. Extraction recoveries of 70 urinary ste
recoveries were calculated by comparing pea
non-extracted counterparts.
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Figure 2. A representative total ion chroma
detection of 70 urinary steroids.different concentrations. The devised method was
found to be linear (correlation coefficient, r2 0.994) for
all analytes, except for cholesterol (r2  0.983). Most
compounds had an LOQ in the 0.05 2.0 ng/mL range,
while those of DHEA, Epi-An, 5-dione, -diol,
11-dehydroB, 17-OH-Preg, and 11-OH-Prog ranged
between 5.0 and 50 ng/mL (Table 2).
Assay precisions and accuracies were determined by
analyzing three QC samples at different concentrations
of the individual steroids (5, 20, 100, 200, 500, and 2000
ng/mL). Intra-day (n  4) precisions (expressed as %
CV) ranged from 0.9% to 11.2%, whereas accuracies
(expressed as % bias) ranged from 95.8 to 119.1%, and
inter-day (n  5) precisions (% CV) and accuracies (%
bias) ranged from 1.6% to 10.5% and from 91.6% to
115.5%, respectively (Table 2). Especially, the accuracy
analyzed using the described method. Absolute
ight ratios of extracted samples versus their
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Compounds (trivial name)
LODa
(ng/mL)
LOQb
(ng/mL)
Calibration
range (ng/mL)
Linearity
(r2)
intra-day (n  4) inter-day (n  5)
CVc
(%)
Accuracyc
(%)
CV
(%)
Accuracy
(%)
Androgens
-diol 0.5 1.0 1–200 0.998 5.9 104.0 3.8 97.9
-diol 0.2 0.5 0.5–200 0.998 5.7 107.8 3.1 105.0
An 0.1 0.5 0.5–3000 0.996 3.2 119.1 3.5 108.8
Etio 0.1 0.5 0.5–3000 0.998 2.5 106.1 2.2 109.7
-diol 0.5 1.0 1–200 0.998 6.8 111.4 3.3 109.6
-diol 0.2 0.5 0.5–200 0.998 4.4 106.2 3.0 109.1
-diol 1.0 2.0 2–200 0.995 5.2 107.5 3.4 103.4
Epi-DHT 0.1 0.2 0.2–200 0.994 8.0 106.0 3.4 108.9
11-keto-An & Etio 0.1 0.5 0.5–1000 0.996 3.7 108.4 3.4 112.3
DHEA 5.0 50.0 50–3000 0.997 3.5 106.6 3.3 108.2
Epi-An 2.0 5.0 5–1000 0.994 2.5 98.0 2.1 109.5
A-diol 0.5 2.0 2–200 0.996 7.4 116.3 10.5 97.2
5-dione 0.5 5.0 10–200 0.995 4.8 106.2 2.2 111.8
Epi-T 0.05 0.1 0.1–200 0.997 3.8 100.7 1.6 100.8
-diol 10.0 20.0 20–500 0.998 6.9 104.0 3.0 104.0
DHT 0.1 0.2 0.2–200 0.998 4.7 109.6 2.4 102.7
A-dione 0.05 0.1 0.1–200 0.999 5.7 103.4 2.4 101.7
T 0.05 0.1 0.1–200 0.998 4.7 106.1 1.9 102.5
11-OH-An 0.2 0.5 0.5–3000 0.997 3.4 104.6 5.8 112.9
11–OH-Etio 0.2 0.5 0.5–3000 0.998 2.7 101.3 4.1 113.4
16-OH-DHEA 0.1 0.2 0.2–1000 0.996 4.0 104.3 1.7 105.8
Estrogens
17-E2 0.05 0.1 0.1–200 0.998 3.9 98.6 2.6 96.3
E1 0.1 0.2 0.2–200 0.998 2.9 99.0 2.0 97.3
17-E2 0.05 0.1 0.1–200 0.997 3.5 99.8 2.3 97.2
2-MeO-E2-3-methylether 0.1 0.2 0.2–200 0.998 2.9 97.3 2.1 96.4
4-MeO-E2 0.2 0.5 0.5–200 0.998 2.1 98.7 1.8 95.6
2-MeO-E1 0.05 0.1 0.1–200 0.998 1.9 99.0 1.8 95.8
2-OH-E2-3-methylether 0.1 0.2 0.2–200 0.998 4.2 101.3 2.4 97.6
2-MeO-E2 0.05 0.1 0.1–200 0.998 4.3 100.2 2.2 97.1
2-OH-E1 0.1 0.2 0.2–200 0.998 4.9 104.7 3.7 99.5
2-OH-E2 0.1 0.2 0.2–200 0.998 6.1 106.4 3.4 99.3
4-OH-E1 0.1 0.2 0.2–200 0.998 2.9 103.2 2.5 98.8
4-OH-E2 0.1 0.2 0.2–200 0.998 4.6 100.1 4.2 97.3
17-epi-E3 0.5 1.0 1–200 0.997 2.4 106.7 2.4 100.3
E3 0.2 0.5 0.5–200 0.997 2.7 101.6 2.8 99.7
16-keto-E2 and 16-OH-E1 0.1 0.2 0.2–500 0.998 2.7 98.7 8.8 92.5
16-epi-E3 0.5 1.0 1–200 0.997 3.5 103.2 2.3 100.5
2-OH-E3 0.5 1.0 1–100 0.997 5.0 107.4 5.3 101.0
Corticoids
THS 0.1 0.2 0.2–200 0.997 0.9 99.2 3.0 98.4
THDOC 0.2 0.5 0.5–200 0.996 7.1 100.4 4.1 100.0
THE 1.0 2.0 2–500 0.997 7.6 151.4 9.9 151.3
THF 0.2 0.5 0.5–200 0.998 6.6 106.1 4.9 104.0
DHDOC 0.5 1.0 1–200 0.997 4.2 101.2 4.1 104.9
Allo-THF 0.2 0.5 0.5–500 0.996 4.8 103.9 2.6 102.6
21-deoxyF 0.5 1.0 1–200 0.997 7.3 108.5 4.8 109.3
11-deoxyF 0.2 0.5 0.5–200 0.998 2.9 98.5 3.5 91.6
11-deoxyB 0.5 1.0 1–200 0.997 6.9 100.3 2.9 105.1
Cortisone (E) 0.2 0.5 0.5–500 0.998 3.2 101.2 2.7 99.8
11-dehydroB 0.2 5.0 5–200 0.994 2.1 101.8 2.7 100.4
Allo-DHB 0.5 1.0 1–200 0.997 6.9 113.1 5.3 108.0
Allo-DHF 1.0 2.0 2–200 0.997 2.3 97.5 2.9 107.3
Corticosterone (B) 0.2 0.5 0.5–200 0.997 3.3 99.0 3.3 100.3
Cortisol (F) 0.1 0.2 0.2–200 0.998 3.0 100.5 3.5 98.0
Progestins
5-DHP 0.1 0.2 0.2–100 0.997 9.9 109.2 3.5 110.5
Epi-P-one 1.0 2.0 2–200 0.995 4.1 106.0 3.0 105.8
P-one 1.0 2.0 2–200 0.997 7.4 110.1 3.3 115.5
Allo-P-one 0.2 0.5 0.5–200 0.994 2.9 109.9 2.2 103.7
taine
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produced by low calibration slope because of poor
GC-MS properties.
Quantitative Results of Benign Prostatic
Hyperplasia
The validated quantitative profiling method was ap-
plied to measure 70 endogenous steroids in urine
samples obtained from 59 BPH patients and 41 age-
matched healthy male subjects. All quantitative results,
corrected by urinary creatinine levels, were compared,
and differences between patients and healthy subjects
were evaluated using the Student’s t-test. Although it
was not the purpose of this study to elucidate clinical
implications, some features were notable, and signifi-
cant differences were found between patients and
healthy subjects (see Supplementary Figure 2).
In patients, urinary levels of T, Epi-T, -diol,
-diol, -diol, 17-E2, 11-OH-Prog, and 16-OH-
DHEA were significantly decreased (P  4.52  10–4 
2.77  10–13), and those of 11-OH-Etio, -diol,
2-OH-E3, 17-OH-Prog, and 11-deoxyF were signifi-
cantly increased (P  4.56  10–7  9.42  10–18). Some
other urinary steroids quantified were also significantly
different in patients and controls (P  0.01). Changes in
the urinary levels of -diol and -diol were in
accord with previous findings [36, 37], but other steroid
changes observed in this study have not been reported
to date. In particular, urinary 17-E2 and 2-OH-E3
showed remarkable changes with P values of 2.77 
10–13 and 4.25  10–9, which might be associated with
the different biochemical roles of estrogen receptor 
(ER) and  (ER) in various types of prostate cells [28, 38,
39]. The involvements of other urinary steroids needs to
Table 2. Continued
Compounds (trivial name)
LODa
(ng/mL)
LOQb
(ng/mL)
Cali
range
P-diol 0.5 1.0 1
P-triol 0.2 0.5 0.5
Preg 1.0 2.0 20
5-DHP 0.2 0.5 0.5
Prog 0.5 1.0 1
20-DHP 0.2 0.5 0.5
17-OH-Preg 5.0 10.0 20
17-OH-Prog 0.2 0.5 0.5
11-OH-Prog 2.0 5.0 5
Sterols
Chol 1.0 2.0 50
24S-OH-Chol 0.5 2.0 2
aThe limit of detection was measured S/N ratio  3.
bThe limit of quantification was measured S/N ratio  10.
cPrecision and accuracy were expressed as the mean values of data obfuture study.Steroid Signatures by Hierarchical Clustering
Analysis
The present MS-based steroid profiling has become an
essential clinical tool and has produced many results in
BPH, but it is difficult to identify critical differences
between patients and controls because of the large
number of results. Hierarchical clustering, which in-
volves calculating the distance matrices of data objects
and then merging objects that are close to each other to
form sub-clusters, has been utilized in biomedical stud-
ies to interpret the expressions of biomolecules [2,
22–25]. In the present study, after determining the
relative levels of each steroid, all data were z-score
transformed to produce a heat map using a supervised
HCA based on Pearson’s correlation coefficient. The
raw data were the relative concentrations of the 70
urinary steroids, and these were filtered by statistical
significance (P  0.01) using the Student’s t-test. The
clustering method and similarity measure were set
unweighted average and Euclidean distance, respec-
tively. Urinary concentrations were represented by col-
ors in the heat map, and each steroid was represented
by a single row of colored boxes, whereas columns
represented different subjects. Heat maps were com-
pared with respect to individual quantitative results,
and indicated the effectiveness of steroid signatures.
Figure 3 illustrates in a heat map showing altered
concentrations of urinary steroids in BPH patients and
healthy subjects. The heat map readily shows changes in
the concentrations of urinary steroids. Increased urinary
excretion patterns of several steroids, from Epi-DHT
down to 11-deoxyF, were detected in patients, while other
steroid levels were significantly reduced. In addition,
visual inspections of steroid signatures complemented
quantitative statistics. Although 2-OH-E3 was present at a
significantly higher level in patients (P  4.25  10–9; see
on
mL)
Linearity
(r2)
intra-day (n  4) inter-day (n  5)
CVc
(%)
Accuracy
c (%)
CV
(%)
Accuracy
(%)
0.997 6.2 105.6 3.6 107.5
0.999 6.0 102.8 2.3 105.5
0.995 8.8 104.1 3.5 98.5
0.995 7.0 99.2 3.8 104.0
0.998 4.8 96.0 2.5 98.6
0.997 9.1 101.7 4.9 103.8
0.998 3.6 98.7 3.0 102.9
0.996 3.1 95.8 2.3 96.1
0.996 11.2 103.9 7.3 94.3
0 0.983 7.3 113.0 7.8 115.0
0.994 6.5 96.3 4.1 100.9
d from three different concentrations for each analyte.brati
(ng/
–500
–500
–200
–200
–100
–100
–500
–200
–500
–100
–200Supplementary Figure 2), these increases were only ob-
1635J Am Soc Mass Spectrom 2009, 20, 1626–1637 QUANTITATIVE STEROID SIGNATURES BY GC-MSserved in some patients in the heat map. The levels of
other steroids, 11-OH-Etio and 11-deoxyF, were also
inconsistency different in patients (Figure 3).
To illustrate further the usefulness of a steroid sig-
nature, the ratio of steroid metabolite to precursor,
which reflects enzyme activity (Scheme 1), was exam-
ined. The cluster and heat maps of all analyzed sam-
ples in this 70 compound study showed differences
between groups in these ratios (Figure 4). A dendro-
gram of ratios revealed that the oxidoreductases
formed a cluster (5-reductase, 3-HSD, 3-HSD, and
17-HSD, except for 20-HSD; see Supplementary
Table 1 for full enzyme names), which are differenti-
ated with a cytochrome P450 enzyme, 11-hydroxy-
lase. These results support the validity of the data
transformation, since 5-reductase is a marker of
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Figure 3. Hierarchically clustered heat map of
healthy male subjects. Differences between ste
using Student’s t-test, and only those that wer
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Figure 4. A heat map for measuring enzyme
precursor to metabolite for each steroid was c
significant at the P  0.01 level were selected. R
Red represents a high ratio and blue a low ratio.BPH [27–29], and 17-HSD is positively expressed in
prostate cells [40, 41]. Other up-regulated enzymes in
the map might be biomarkers of BPH. Furthermore,
the method can be used to visualize quantitative
steroid data in a single graphic using a hierarchically
clustered heat map. The need for this type of visual-
ization arises from the complexity of large experi-
mental datasets. One important advantage of using a
heat map is that it can be used to visualize clinical
data across multiple subjects for many analytes,
which allows patterns to be easily identified.
Conclusions
Due to the clinical requirement to quantify trace levels
of urinary endogenous steroids, we devised an analyt-
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1636 MOON ET AL. J Am Soc Mass Spectrom 2009, 20, 1626–1637ical method to measure the individual concentrations of
70 urinary steroids and several enzyme activities based
on steroid signatures using a single assay, which sub-
stantially reduces analytical time and sample size. In
contrast to classical biochemical approaches using RIA
and EIA that mainly focus on single enzymes, single
metabolic reactions, and kinetic properties, profiling
analysis involves the collation of quantitative results for
a broad series of metabolites to gain an overall under-
standing of metabolism.
Steroid signatures as represented by hierarchically
clustered heat maps use color to communicate under-
lying quantitative results, which are much harder to
appreciate when presented numerically. This method is
simple to implement and maintains the biological in-
tegrity of data. Using this technique, inter-relationships
between absolute concentrations and enzyme activities
in samples from different sources can be recognized.
The combined GC-MS profiling technique described
has adequate sensitivity that could be used for high
throughput analysis, and could be adopted to enable
the quantifications of urinary steroids and indicate
metabolic alterations at biologically relevant levels.
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